Benazepril and weight - long- was:Benzapril versus Enalapril
Both enalapril and benazepril are ACE-inhibitors, but
not the same drug. I am not familiar with any feline
directly comparing one to the other, but I have not
as careful a watch on feline veterinary literature as
I once was.
As far as benazepril and increased appetite I have
of the study that you most likely refered to. (I have
of the study if anyone would like one).
J Vet Pharmacol Ther. 2006 Jun;29(3):225-7
Benazepril increases feed intake and body weight in
healthy growing cats
J. N. KING*,
S. KING &
*Novartis Animal Health Inc., Basel, Switzerland;
Novartis Animal Health Inc., Greensboro, NC, USA; MPI
Research, Mattawan, MI, USA
Twenty-four ... cats aged approximately 7 months and
weighing 2.54.5 kg ... were randomized into groups.
Six female and six male cats were dosed with 2 mg/ kg
benazepril.HCl (FORTEKOR 5, Novartis Animal Health
Inc., Basel, Switzerland) orally once daily for 52
weeks. The dosage represents a small overdose when
compared with the therapeutic dosage of 0.51 mg/kg of
benazepril.HCl in cats (The BENRIC Study Group, 2006).
The control group consisted of six female
and six male cats, which were sham-dosed each day (the
identical procedures were followed as for oral dosing
benazepril but no test article was administered).
Cats ... were fed a complete commercial diet
(Certified Cat Chow #5003, PMI Nutrition
St Louis, Mo, USA). Water was provided ad libitum.
Statistical analyses were conducted using repeated
ANOVA. Significance was defined with P < 0.05.
Body weights (P ¼ 0.39) and food consumption (P ¼
were not significantly different between the
control groups at baseline, but were significantly
higher in the
benazepril group during treatment (Figs 1 and 2) with
P ¼ 0.03
for body weight and P < 0.0001 for food consumption.
Although there were marked differences in body weights
between males and female cats, significantly (P <
body weights were observed in the benazepril group for
males and females.
Food consumption was significantly
higher in benazepril-treated animals when compared
control group in male cats (+13.9%, P < 0.0001), but
significance was not reached in female (+11.6%, P >
Secondly, ACEI have been reported to increase appetite
inhibit loss of body weight in patients with chronic
Benazepril increased appetite in dogs with congestive
failure in one clinical trial (Kitagawa et al., 1997).
with chronic heart disease, ACEI reduce the risk of
and possible mechanisms include reduction of levels of
or the inflammatory mediators tumour necrosis factor
(TNF) or C-reactive protein (Anker et al., 2003).
alternative mechanism for improved appetite in
congestive heart failure could be secondary to
cardiovascular function. However, we judge it unlikely
increased cardiovascular function or reduced
mediators played a significant role in increasing the
and body weight of the cats in our study as they were
Increased food intake or body weights have not been
previously with other ACEI in cats, dogs or rodents.
In fact high
doses of some ACEI may reduce appetite or body weight
et al., 1993; Donaubauer & Mayer, 1988). No effects of
treatment with enalapril (body weight) or imadapril
weight or food consumption) were observed in healthy
(Sanders et al., 1992; Thoulon et al., 2003).
Therefore, it seems
possible that the effects noted in our trial with
benazepril are due
to an additional property of this molecule in cats and
reflect a class effect of ACEI in this species.
Cats with heart or kidney disease frequently have
appetite and/or poor body condition and therefore
would be useful clinically if it increased food
body weight in diseased animals. It must be
however, that the cats in our study were young
7 months), growing and healthy, and the same effects
occur in older, diseased or convalescent cats.
increased appetite in highly proteinuric (urine
ratio [UPC]P1) cats with chronic kidney disease,
although no significant effects on either appetite or
were observed in animals with UPC < 1 (The BENRIC
There are also a couple of recent studies regarding
and renal failure. Again, there was no comparison to
ACE-inhibitors. I do not have copies of these
J Vet Intern Med. 2006 Sep-Oct;20(5):1074-9.
Evaluation of the clinical efficacy of benazepril in
the treatment of chronic renal insufficiency in cats.
Mizutani H, Koyama H, Watanabe T, Kitagawa H, Nakano
M, Kajiwara K, King JN.
Division of Veterinary Internal Medicine, Nippon
Veterinary and Life Science University, Tokyo, Japan.
BACKGROUND: Chronic renal insufficiency (CRI) is a
common disease in cats. Angiotensin-converting enzyme
inhibitors (ACEI) have beneficial effects in humans
with CRI by reducing the loss of protein in the urine
and increasing life expectancy. HYPOTHESIS: The ACEI
benazepril has beneficial effects on survival,
clinical variables, or both as compared with placebo
in cats with CRI. ANIMALS: 61 cats with naturally
METHODS: The cats were enrolled into a prospective,
randomized, double-blind, placebo-controlled clinical
trial. Cats received placebo or 0.5-1 mg/kg benazepril
once daily for up to 6 months.
RESULTS: Urine protein/urine creatinine ratios were
significantly (P < .05) lower with benazepril as
compared with placebo at days 120 and 180. Three cats
with placebo and 1 cat with benazepril were removed
prematurely from the study because of deterioration of
CRI or death. Cats were classified into 4 stages of
CRI according to the International Renal Interest
Society (IRIS) classification scheme. Incidence rates
of cats with IRIS classification stage 2 or stage 3
that remained in stage 2 or 3 without progressing to
stage 4 were higher with benazepril (93 +/- 5%) as
compared with placebo (73 +/- 13%).
CLINICAL IMPORTANCE: These results suggest a potential
for benazepril to delay the progression of disease,
extend survival time, or both in cats with CRI.
This study is from Novartis again - the maker of the
I have read that an artificial kidney failure system
is used by
this group that may or may not reflect natural
J Vet Intern Med. 2006 Sep-Oct;20(5):1054-64.
Tolerability and efficacy of benazepril in cats with
chronic kidney disease.
King JN, Gunn-Moore DA, Tasker S, Gleadhill A,
Strehlau G; Benazepril in Renal Insufficiency in Cats
Novartis Animal Health Inc, Postfach, Basel,
The objective of the study was to test the effect of
the angiotensin-converting enzyme inhibitor (ACEI)
benazepril in cats with chronic kidney disease (CKD).
A total of 192 cats with CKD with an initial plasma
creatinine concentration > or = 2 mg/dL (> or = 177
micromol/L) and urine specific gravity < or = 1.025
were recruited into a double-blind, parallel-group,
prospective, randomized clinical trial. Cats received
daily (q24h) PO placebo (n = 96) or benazepril x HCl
at a dosage of 0.5-1.0 mg/kg (n = 96) for up to 1,119
days. Most cats were fed exclusively a diet containing
low amounts of phosphate, protein, and sodium.
Benazepril produced a significant reduction in
proteinuria, assessed by the urine
protein-to-creatinine ratio (UPC, P = .005). This
effect of benazepril was present in all subgroups
tested, including cats with UPC <0.2, although the
effect was largest in cats with higher UPCs. Plasma
protein was maintained at higher concentrations with
benazepril as compared with placebo during treatment
in cats with initial UPC <1 (P = .038 versus P = .079
for all cats). There was no difference in renal
survival time between the 2 groups when all 192 cats
were compared. Mean +/- SD renal survival times were
637 +/- 480 days with benazepril and 520 +/- 323 days
with placebo (P = .47). Mean +/- SD renal survival
times in the 13 cats with initial UPC > or = 1 were
402 +/- 202 days with benazepril and 149 +/- 90 days
with placebo (P = .27). Cats with initial UPC > or = 1
treated with benazepril had better appetite (P = .017)
as compared with those treated with placebo.
Benazepril was well tolerated. In conclusion,
benazepril decreased proteinuria in cats with CKD.
Study related to benazepril and HCM - not terribly
robust - not clear
that heart changes were due to the drug (I do have a
copy of this
study if anyone would like one).
Can Vet J. 2006 May;47(5):437-45. Links
Benazepril and subclinical feline hypertrophic
cardiomyopathy: a prospective, blinded, controlled
Taillefer M, Di Fruscia R.
Companion Animal Research Group, Small Animal
Veterinary Teaching Hospital, Université de Montréal,
3200, Sicotte Street, PO Box 5000, Saint-Hyacinthe,
Quebec J2S 7C6. mylene.taillefer@...
Twenty-one cats with hypertrophic cardiomyopathy were
enrolled in this study to determine if the
administration of benazepril (0.5 mg/kg body weight
[BW], PO, q24h) to cats with subclinical hypertrophic
cardiomyopathy improves cardiac diastolic function and
reverses left ventricular hypertrophy when compared
with diltiazem controlled delivery (CD) (10 mg/kg BW,
PO, q24h). Cats were evaluated at day 0 and after 3
and 6 months of therapy. In the benazepril group (n =
11), the diastolic transmitral flow of the E and A
waves ratio (E/A ratio) increased significantly
between 0 and 6 months (P = 0.009) and the thickness
of the left ventricular free wall in systole (LVFWs)
decreased significantly between 0 and 3 months (P =
0.04). In the diltiazem CD group (n = 5), none of the
parameters varied significantly throughout the study.
There was no difference between the benazepril and the
diltiazem CD group throughout the study. Therefore,
the variations observed for the E/A ratio and the
LVFWs may have been incidental. Further studies will
be needed to establish the role of benazepril in
subclinical hypertrophic cardiomyopathy in cat.
Be a better Heartthrob. Get better relationship answers from someone who knows. Yahoo! Answers - Check it out.